Connect with us

Hi, what are you looking for?

Jewish Business News


Can-Fite BioPharma Liver Drug Gets US Patent


Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a patent in the US for its drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery.

The issued patent # 8, 846, 635 is titled, “Method for inducing hepatocyte proliferation and uses thereof.”

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Can-Fite has also recently been granted patents for this technology in both Japan and the European Union.

CF102 is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly expressed in tumor cells whereas low expression is found in normal cells. According to the company, this differential effect accounts for the excellent safety profile of the drug.

The new drug is now entering Phase II trials for the treatment of hepatocellular carcinoma, the most common form of liver cancer in the U.S., Europe and Israel. The U.S. Food and Drug Administration has granted Orphan Drug Status to Can-Fite’s CF102 for this indication and Israel’s Ministry of Health has approved CF102 for Compassionate Use in liver cancer.

“The treatment of post-surgery liver function is an indication that would complement our current portfolio of indications in clinical trials. CF102 may offer important healing benefits for the liver not only to cancer patients, but also for patients who have other diseases or injuries of the liver, ” stated Can-Fite CEO Pnina Fishman.

In preclinical studies, CF102 has induced proliferation of hepatocytes following liver resection (surgery), increased liver weight and reduced elevated levels of serum liver enzymes, reflecting improved liver status. In patients with preexisting liver diseases, such as cirrhosis or cancer, normal hepatocellular proliferation following injury is impaired, exposing patients to liver dysfunction and associated complications that can lead to liver failure and death.

Can-Fite’s intellectual property portfolio consists of 150 issued and pending patents worldwide. Additional patents relating to induction of hepatocyte proliferation and uses thereof are pending in several other markets, including Israel.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News